SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to widespread user outages linked to an AWS issue, sparking frustration and concerns about reliability as users were unable to access accounts or trade. Despite the disruption, the stock price has shown surprising resilience, leading to discussions on market dynamics and potential short squeezes. Community members are debating the platform's dependence on a single server and comparing it to competitors, while some speculate about manipulation.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology ($GSIT) is trending due to news of a Cornell-led paper validating its Compute-In-Memory Gemini-I APU, showing comparable throughput to NVIDIA GPUs with significantly lower energy consumption. The stock is seeing increased interest as community members discuss its potential to compete with major players in the AI chip market, with some speculating about potential buyout offers. Community members are also discussing short squeezes.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle $ORCL is trending as analysts attend Oracle's analyst day, where executives outlined impressive targets for fiscal year 2030, including revenue and EPS well ahead of consensus. The community is actively discussing whether these targets are achievable, especially given concerns around AI infrastructure spending and profitability, while some are pointing towards a potential pullback.

Aventus Network

Aventus Network ($AVT) is trending as the community discusses its potential, particularly highlighting its integration with Polkadot for interoperability. Recent news includes the founder's feature in Forbes discussing the future of agentic AI and its implications for blockchain. Some investors are noting the low market cap relative to its technology and partnerships.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune ($REPL) is trending due to news of the FDA accepting the resubmission of its Biologics License Application for RP1, a melanoma treatment, leading to significant price movement and trading volume. Community discussions revolve around updated price targets, the potential for a short squeeze, and collaborations with major pharmaceutical companies. However, some traders express caution, citing the long PDUFA timeline and potential for a pump and dump.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

Recent news regarding the company's CEO taking a board seat at TLPH is sparking community interest, especially given CRMD's strategic investment in TLPH. Some investors speculate about a potential acquisition, while others are focused on upcoming clinical data for TLPH's Niyad and its potential impact on CRMD's growth. Bullish sentiment seems to be driven by institutional buying and anticipation of upcoming earnings and guidance.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as the company explores rare earth production at its U.S. mining sites, potentially pivoting from steel to strategic minerals. Community members are weighing in on the CEO's vision, buyout possibilities, and the potential impact of this move on debt reduction and shareholder value. Some traders express concerns about the CEO's past performance and the sustainability of the recent surge.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 and is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance (PSKY) is trending amid discussions of a potential acquisition of Warner Bros. Discovery (WBD), with speculation around deal terms and potential involvement of private equity firms like Apollo. The community is actively debating the likelihood of a deal, potential bidding wars, and the impact on PSKY's valuation, with some viewing layoffs as a positive sign of cost optimization post-merger. Discussions also include potential impacts from new partnerships, streaming strategies (UFC) and key executive hires.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending as discussions revolve around positive clinical data for their KRAS G12D inhibitor, offset by concerns about management spending and potential dilution; the community is weighing the promising ORR data against alternative treatments and the company's history, with some anticipating a potential breakout or buyout, while others express frustration with management and short selling.

PIMCO Dynamic Income Fund is a non-diversified, closed-end management investment company. Its seeks current income as a primary objective and capital appreciation as a secondary objective. The company was founded on January 19, 2011 and is headquartered in New York, NY.

PIMCO Dynamic Income Fund

PDI is experiencing volatility, driven by a recent downgrade and discussions around its premium to NAV and dividend coverage amid higher interest rates, sparking community debate on whether to buy the dip or brace for further declines. Community members are actively debating whether this dip represents a buying opportunity or signals deeper problems within the fund, with some citing attractive monthly payouts and high yield. The fund's reliance on leverage and high-yield credit in a challenging rate environment adds to the uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?

CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.

<ul class="summary-bullets"><li>CorMedix said it was raising its fiscal 2025 pro forma net revenue guidance to at least $375 million.</li><li>The company said the third-quarter unaudited DefenCath net revenue came in at more than $85 million.</li><li>DefenCath is a drug used for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter.</li></ul>CorMedix Inc. (CRMD) stock became the top trending ticker on Stocktwits after the shares jumped 12% in premarket trading following the biopharmaceutical company raising its annual net revenue forecast on Monday.The company said it was raising its fiscal 2025 pro forma net revenue guidance to at least $375 million, up from a prior forecast of $325 million to $350 million.<h2 class="st-heading-2">What Is The Company’s Expectation For Q3?</h2>CorMedix said that preliminary third-quarter unaudited results showed net revenue of more than $100 million, including at least $85 million for DefenCath, and preliminary pro forma third-quarter unaudited company net revenue of more than $125 million.CorMedix has been working on DefenCath (taurolidine and heparin) for the prevention of catheter-related bloodstream infections in adult patients undergoing hemodialysis via a central venous catheter.The company said DefenCath revenue growth has been driven by stronger-than-projected utilization by the company’s Large Dialysis Organization (LDO) customer, as well as continued utilization growth with other customers.Get updates to this developing story directly on Stocktwits.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/delta-united-airlines-affected-by-aws-disruption-report/ch6CMB4R3Yi">Delta, United Airlines Affected By AWS Disruption: Report</a>

CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast?

CorMedix said it was raising its fiscal 2025 pro forma net revenue guidance to at least $375 million.

Equity

Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX

ATXS stock jumps 37% after agreeing to a $700 million cash-and-stock buyout by BioCryst, boosting the latter's HAE treatment pipeline.

CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?

CRMD shares slip 16%, but rising DefenCath sales and the Melinta deal can set the stage for renewed growth.

FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months 

Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.


Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In?

CRMD's DefenCath gives the company a first-mover edge in CRBSI prevention, but looming heparin giants test how long its lead can last.

GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal

Genmab stock surges 21.9% after striking an $8 billion deal to buy Merus, adding a late-stage cancer treatment candidate to its proprietary oncology pipeline.

ILMN Stock Set to Benefit From the Launch of New BioInsight Division

Illumina launches BioInsight to harness multiomic data, accelerate drug discovery, and boost disease diagnosis.

ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves

AngioDynamics posts narrower-than-expected Q1 loss, 12% revenue growth and margin gains; it also raises FY26 sales outlook, sending shares higher.

CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program

Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

CRMD
CorMedix Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CRMD News

CRMDCorMedix Inc